Breaking News Instant updates and real-time market news.

STJ

St. Jude Medical

$79.44

1.78 (2.29%)

, ABT

Abbott

$41.17

0.58 (1.43%)

07:17
10/19/16
10/19
07:17
10/19/16
07:17

St. Jude Medical says 'excited' about Abbott transaction

Commenting on the company's financial results, St. Jude Medical (STJ) President and CEO, Michael T. Rousseau said, "Third quarter results continue to confirm that our innovation based growth strategy is on track. As we continue to establish ourselves as the global technology leader in our markets, our focus is on bringing new technology to patients in the fourth quarter and throughout 2017 that will elevate current standards of care while reducing the cost of healthcare. We also remain excited about the Abbott (ABT) transaction, which we continue to expect to close in the fourth quarter of 2016." As previously announced, St. Jude Medical has changed its sales reporting to more closely align with how the company manages the business in five key areas: atrial fibrillation, heart failure, neuromodulation, cardiovascular and traditional cardiac rhythm management. AF product sales for the third quarter totaled $316 million, a 14 percent increase on a reported basis and a 12 percent increase on a constant currency basis compared to the prior year quarter. HF product sales, which include cardiac resynchronization therapy products, HeartMate ventricular assist devices and the CardioMEMS HF System, totaled $351 million for the third quarter, a 46 percent increase compared to the prior year quarter. St. Jude Medical sales of neuromodulation products were $141 million in the third quarter of 2016, a 17 percent increase on both a reported and constant currency basis compared to the prior year quarter. Total cardiovascular sales were $313 million for the third quarter of 2016, an increase of 8 percent compared to the prior year quarter. Total CRM sales, which include single and dual chamber implantable cardioverter defibrillator and pacemaker products, were $378 million for the third quarter of 2016, a 7 percent decline on both a reported and constant currency basis compared to the third quarter of 2015.

STJ

St. Jude Medical

$79.44

1.78 (2.29%)

ABT

Abbott

$41.17

0.58 (1.43%)

  • 19

    Oct

  • 19

    Oct

  • 21

    Oct

  • 26

    Oct

  • 06

    Nov

STJ St. Jude Medical
$79.44

1.78 (2.29%)

10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

TODAY'S FREE FLY STORIES

HOG

Harley-Davidson

$59.76

-2.31 (-3.72%)

14:50
12/02/16
12/02
14:50
12/02/16
14:50
Technical Analysis
Harley-Davidson hits session lows, levels to watch »

The shares are down 4% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$68.22

2.25 (3.41%)

14:48
12/02/16
12/02
14:48
12/02/16
14:48
Recommendations
Eli Lilly analyst commentary  »

Eli Lilly expanded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 15

    Dec

P

Pandora

$12.90

1.4152 (12.33%)

, SIRI

Sirius XM

$4.56

-0.015 (-0.33%)

14:47
12/02/16
12/02
14:47
12/02/16
14:47
Periodicals
Pandora advisers said to talk to possible suitors, Bloomberg says »

Bloomberg added that…

P

Pandora

$12.90

1.4152 (12.33%)

SIRI

Sirius XM

$4.56

-0.015 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIBR

Oi S.A.

14:47
12/02/16
12/02
14:47
12/02/16
14:47
Periodicals
Oi could scrap restriction on debt-for-equity swap, Reuters says »

Brazil's Oi could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVTB

PrivateBancorp

$48.78

2 (4.28%)

, CM

CIBC

$81.64

0.26 (0.32%)

14:41
12/02/16
12/02
14:41
12/02/16
14:41
Hot Stocks
Alpine Associates opposes PrivateBancorp's acquisition by CIBC »

Alpine Associates…

PVTB

PrivateBancorp

$48.78

2 (4.28%)

CM

CIBC

$81.64

0.26 (0.32%)

KRE

SPDR S&P Regional Banking ETF

$53.05

-0.415 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMX

BioPharmX

$0.38

0.0729 (23.52%)

14:38
12/02/16
12/02
14:38
12/02/16
14:38
Hot Stocks
Breaking Hot Stocks news story on BioPharmX »

Vivo Capital VIII reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$118.87

0.36 (0.30%)

14:37
12/02/16
12/02
14:37
12/02/16
14:37
Hot Stocks
Celgene agrees to complete acquisition of Acetylon »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

  • 06

    Dec

KVHI

KVH Industries

$10.85

-0.05 (-0.46%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Hot Stocks
KVH Industries names Donald Reilly CFO »

KVH Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$109.28

-2.37 (-2.12%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Options
GW Pharmaceuticals put volume heavy and directionally bearish »

Bearish flow noted in GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

, RUT

Russell 2000 Index

14:23
12/02/16
12/02
14:23
12/02/16
14:23
Technical Analysis
On The Fly: Weekly technical notes for the Russell 2000 »

The index at time of…

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$189.72

-1.76 (-0.92%)

14:21
12/02/16
12/02
14:21
12/02/16
14:21
Recommendations
Mohawk analyst commentary  »

Mohawk a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.20

0.32 (2.48%)

14:15
12/02/16
12/02
14:15
12/02/16
14:15
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

14:15
12/02/16
12/02
14:15
12/02/16
14:15
General news
Fedspeak will be compressed next week »

Fedspeak will be…

EDU

New Oriental Education

$47.96

-1.03 (-2.10%)

14:08
12/02/16
12/02
14:08
12/02/16
14:08
Periodicals
New Oriental Education engaged in college application fraud, Reuters says »

Former and current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

, SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

14:07
12/02/16
12/02
14:07
12/02/16
14:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
12/02/16
12/02
14:05
12/02/16
14:05
General news
Oil rallies while equities stall »

Stocks have stalled out,…

TITN

Titan Machinery

14:02
12/02/16
12/02
14:02
12/02/16
14:02
Downgrade
Titan Machinery rating change  »

Titan Machinery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

, BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

14:01
12/02/16
12/02
14:01
12/02/16
14:01
Hot Stocks
Sonoco to invest $20M in new Atlanta packaging center to support Duracell ops »

Sonoco (SON) announced it…

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

BRK.B

Berkshire Hathaway

$159.07

-1.05 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 02

    Dec

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Hot Stocks
Breaking Hot Stocks news story on New Oriental Education »

New Oriental down over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Periodicals
Breaking Periodicals news story on New Oriental Education »

Standards council to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYCC

ClubCorp

$13.40

0.2 (1.52%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Options
Call buyer opens the largest open interest block in ClubCorp options »

Call buyer opens the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
12/02/16
12/02
14:00
12/02/16
14:00
General news
NY Fed accepted $167.88 B in daily reverse repos »

NY Fed accepted $167.88 B…

SBUX

Starbucks

$58.51

0.54 (0.93%)

13:51
12/02/16
12/02
13:51
12/02/16
13:51
Hot Stocks
Starbucks in 'capable hands' after 'surprising' CEO change, analysts say »

Shares of Starbucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.